{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:24:55Z","timestamp":1791959095614,"version":"4.3.4"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nrneurol.2013.107","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T06:48:47Z","timestamp":1370933327000},"page":"371-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Ushering in the study and treatment of preclinical Alzheimer disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Jessica B.","family":"Langbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Fleisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatkamon","family":"Ayutyanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lopera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakeel T.","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Caselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre N.","family":"Tariot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"key":"BFnrneurol2013107_CR1","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association. Alzheimer's Association 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131\u2013168 (2012).","DOI":"10.1016\/j.jalz.2012.02.001"},{"key":"BFnrneurol2013107_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.21915","volume":"67","author":"MM Corrada","year":"2010","unstructured":"Corrada, M. M., Brookmeyer, R., Paganini-Hill, A., Berlau, D. & Kawas, C. H. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann. Neurol. 67, 114\u2013121 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jalz.2010.11.007","volume":"7","author":"R Brookmeyer","year":"2011","unstructured":"Brookmeyer, R. et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 7, 61\u201373 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00002093-200110000-00002","volume":"15","author":"LE Hebert","year":"2001","unstructured":"Hebert, L. E., Beckett, L. A., Scherr, P. A. & Evans, D. A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 15, 169\u2013173 (2001).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrneurol2013107_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/acprof:oso\/9780195328875.003.0020","volume-title":"Imaging the Aging Brain","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. & Langbaum, J. B. in Imaging the Aging Brain (eds Jagust, W. J. & D'Esposito, M.) 319\u2013350 (Oxford University Press, Oxford, 2009)."},{"key":"BFnrneurol2013107_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/bmm.09.91","volume":"4","author":"EM Reiman","year":"2010","unstructured":"Reiman, E. M., Langbaum, J. B. & Tariot, P. N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark. Med. 4, 3\u201314 (2010).","journal-title":"Biomark. Med."},{"issue":"Suppl. 3","key":"BFnrneurol2013107_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-2011-0059","volume":"26","author":"EM Reiman","year":"2011","unstructured":"Reiman, E. M. et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26 (Suppl. 3), 321\u2013329 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2013107_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman, R. J. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1 (2011).","journal-title":"Alzheimers Res. Ther."},{"key":"BFnrneurol2013107_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","volume":"76","author":"PS Aisen","year":"2011","unstructured":"Aisen, P. S. et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280\u2013286 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR10","unstructured":"Food and Drug Administration. Guidance for industry\u2014Alzheimer's disease: developing drugs for the treatment of early stage disease. Food and Drug Administration [online] , (2013)."},{"key":"BFnrneurol2013107_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"BFnrneurol2013107_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-2010-100129","volume":"22","author":"J Valla","year":"2010","unstructured":"Valla, J. et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE \u03b54 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 22, 307\u2013313 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2013107_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","volume":"121","author":"H Braak","year":"2011","unstructured":"Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121, 171\u2013181 (2011).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2013107_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-011-0906-z","volume":"123","author":"A Elobeid","year":"2012","unstructured":"Elobeid, A., Soininen, H. & Alafuzoff, I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 123, 97\u2013104 (2012).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2013107_CR17","doi-asserted-by":"publisher","unstructured":"Knickmeyer, R. C. et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb. Cortex. http:\/\/dx.doi.org\/10.1093\/cercor\/bhs401 .","DOI":"10.1093\/cercor\/bhs401"},{"key":"BFnrneurol2013107_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118\u20131127 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack Jr","year":"2012","unstructured":"Jack, C. R. Jr et al. An operational approach to National Institute on Aging\u2014Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71, 765\u2013775 (2012).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR23","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","volume":"78","author":"DS Knopman","year":"2012","unstructured":"Knopman, D. S. et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576\u20131582 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.neuroimage.2011.11.075","volume":"61","author":"EM Reiman","year":"2012","unstructured":"Reiman, E. M. & Jagust, W. J. Brain imaging in the study of Alzheimer's disease. Neuroimage 61, 505\u2013516 (2012).","journal-title":"Neuroimage"},{"key":"BFnrneurol2013107_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1196\/annals.1379.012","volume":"1097","author":"MJ de Leon","year":"2007","unstructured":"de Leon, M. J. et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1097, 114\u2013145 (2007).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrneurol2013107_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0197-4580(01)00271-8","volume":"22","author":"BC Dickerson","year":"2001","unstructured":"Dickerson, B. C. et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol. Aging 22, 747\u2013754 (2001).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR27","doi-asserted-by":"publisher","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","volume":"2","author":"KA Johnson","year":"2012","unstructured":"Johnson, K. A., Fox, N. C., Sperling, R. A. & Klunk, W. E. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006213 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"BFnrneurol2013107_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1212\/WNL.52.7.1397","volume":"52","author":"CR Jack Jr","year":"1999","unstructured":"Jack, C. R. Jr et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397\u20131403 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/01.wnl.0000180958.22678.91","volume":"65","author":"CR Jack Jr","year":"2005","unstructured":"Jack, C. R. Jr et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65, 1227\u20131231 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.neuroimage.2005.05.015","volume":"27","author":"G Chetelat","year":"2005","unstructured":"Chetelat, G. et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27, 934\u2013946 (2005).","journal-title":"Neuroimage"},{"key":"BFnrneurol2013107_CR31","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1212\/WNL.36.12.1569","volume":"36","author":"PL McGeer","year":"1986","unstructured":"McGeer, P. L. et al. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology 36, 1569\u20131574 (1986).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR32","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1212\/01.wnl.0000281688.77598.35","volume":"70","author":"CR Jack Jr","year":"2008","unstructured":"Jack, C. R. Jr et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 70, 1740\u20131752 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.neuroimage.2008.12.072","volume":"45","author":"JB Langbaum","year":"2009","unstructured":"Langbaum, J. B. et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 45, 1107\u20131116 (2009).","journal-title":"Neuroimage"},{"key":"BFnrneurol2013107_CR34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1126\/science.462184","volume":"205","author":"WJ Schwartz","year":"1979","unstructured":"Schwartz, W. J. et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 205, 723\u2013725 (1979).","journal-title":"Science"},{"key":"BFnrneurol2013107_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/brain\/122.8.1519","volume":"122","author":"K Meguro","year":"1999","unstructured":"Meguro, K. et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122, 1519\u20131531 (1999).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cercor\/6.1.50","volume":"6","author":"PJ Magistretti","year":"1996","unstructured":"Magistretti, P. J. & Pellerin, L. Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. Cereb. Cortex 6, 50\u201361 (1996).","journal-title":"Cereb. Cortex"},{"key":"BFnrneurol2013107_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1523\/JNEUROSCI.17-03-01046.1997","volume":"17","author":"RJ Mark","year":"1997","unstructured":"Mark, R. J., Pang, Z., Geddes, J. W., Uchida, K. & Mattson, M. P. Amyloid \u03b2-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17, 1046\u20131054 (1997).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR38","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","volume":"286","author":"DH Silverman","year":"2001","unstructured":"Silverman, D. H. et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. J. Am. Med. Assoc. 286, 2120\u20132127 (2001).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrneurol2013107_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","volume":"8","author":"MW Weiner","year":"2012","unstructured":"Weiner, M. W. et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 8, S1\u2013S68 (2012).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark, C. M. et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. J. Am. Med. Assoc. 305, 275\u2013283 (2011).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrneurol2013107_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.neuroimage.2007.01.010","volume":"37","author":"RL Buckner","year":"2007","unstructured":"Buckner, R. L. & Vincent, J. L. Unrest at rest: default activity and spontaneous network correlations. Neuroimage 37, 1091\u20131096 (2007).","journal-title":"Neuroimage"},{"key":"BFnrneurol2013107_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1073\/pnas.98.2.676","volume":"98","author":"ME Raichle","year":"2001","unstructured":"Raichle, M. E. et al. A default mode of brain function. Proc. Natl Acad. Sci. USA 98, 676\u2013682 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JGP.0b013e318162a0a9","volume":"16","author":"M Pihlajamaki","year":"2008","unstructured":"Pihlajamaki, M., DePeau, K. M., Blacker, D. & Sperling, R. A. Impaired medial temporal repetition suppression is related to failure of parietal deactivation in Alzheimer disease. Am. J. Geriatr. Psychiatry 16, 283\u2013292 (2008).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2013107_CR46","doi-asserted-by":"publisher","first-page":"18760","DOI":"10.1073\/pnas.0708803104","volume":"104","author":"C Sorg","year":"2007","unstructured":"Sorg, C. et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 104, 18760\u201318765 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR47","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","volume":"25","author":"RL Buckner","year":"2005","unstructured":"Buckner, R. L. et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709\u20137717 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.neuron.2007.10.038","volume":"56","author":"JR Andrews-Hanna","year":"2007","unstructured":"Andrews-Hanna, J. R. et al. Disruption of large-scale brain systems in advanced aging. Neuron 56, 924\u2013935 (2007).","journal-title":"Neuron"},{"key":"BFnrneurol2013107_CR49","doi-asserted-by":"publisher","first-page":"14504","DOI":"10.1073\/pnas.2235925100","volume":"100","author":"C Lustig","year":"2003","unstructured":"Lustig, C. et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc. Natl Acad. Sci. USA 100, 14504\u201314509 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/hbm.20160","volume":"26","author":"SA Rombouts","year":"2005","unstructured":"Rombouts, S. A., Barkhof, F., Goekoop, R., Stam, C. J. & Scheltens, P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum. Brain Mapp. 26, 231\u2013239 (2005).","journal-title":"Hum. Brain Mapp."},{"key":"BFnrneurol2013107_CR51","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","volume":"63","author":"RA Sperling","year":"2009","unstructured":"Sperling, R. A. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178\u2013188 (2009).","journal-title":"Neuron"},{"key":"BFnrneurol2013107_CR52","doi-asserted-by":"publisher","first-page":"12686","DOI":"10.1523\/JNEUROSCI.3189-09.2009","volume":"29","author":"T Hedden","year":"2009","unstructured":"Hedden, T. et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 29, 12686\u201312694 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR53","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/brain\/awr066","volume":"134","author":"A Drzezga","year":"2011","unstructured":"Drzezga, A. et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134, 1635\u20131646 (2011).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cercor\/bhn059","volume":"19","author":"MD Greicius","year":"2009","unstructured":"Greicius, M. D., Supekar, K., Menon, V. & Dougherty, R. F. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb. Cortex 19, 72\u201378 (2009).","journal-title":"Cereb. Cortex"},{"key":"BFnrneurol2013107_CR55","doi-asserted-by":"publisher","first-page":"17763","DOI":"10.1073\/pnas.1010461107","volume":"107","author":"AG Vlassenko","year":"2010","unstructured":"Vlassenko, A. G. et al. Spatial correlation between brain aerobic glycolysis and amyloid-\u03b2 (A\u03b2) deposition. Proc. Natl Acad. Sci. USA 107, 17763\u201317767 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Suppl. 1","key":"BFnrneurol2013107_CR56","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.neurobiolaging.2011.09.003","volume":"32","author":"DM Holtzman","year":"2011","unstructured":"Holtzman, D. M. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol. Aging 32 (Suppl. 1), S4\u2013S9 (2011).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/01.wad.0000191420.61260.a8","volume":"20","author":"LJ Thal","year":"2006","unstructured":"Thal, L. J. et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, 6\u201315 (2006).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrneurol2013107_CR58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan, A. M. et al. Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343\u2013349 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR59","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.21559","volume":"65","author":"AM Fagan","year":"2009","unstructured":"Fagan, A. M. et al. Decreased cerebrospinal fluid A\u03b242 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176\u2013183 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR61","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","volume":"11","author":"AS Fleisher","year":"2012","unstructured":"Fleisher, A. S. et al. Florbetapir PET analysis of amyloid-\u03b2 deposition in presenilin 1 E280A autosomal-dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 11, 1057\u20131065 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR62","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland, T. et al. Decreased \u03b2-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094\u20132103 (2003).","journal-title":"JAMA"},{"key":"BFnrneurol2013107_CR63","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan, A. M. et al. Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343\u2013349 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR64","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0006-3223(99)00143-2","volume":"46","author":"T Sunderland","year":"1999","unstructured":"Sunderland, T. et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry 46, 750\u2013755 (1999).","journal-title":"Biol. Psychiatry"},{"key":"BFnrneurol2013107_CR65","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJM199603213341202","volume":"334","author":"EM Reiman","year":"1996","unstructured":"Reiman, E. M. et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the \u03b54 allele for apolipoprotein E. N. Engl. J. Med. 334, 752\u2013758 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR66","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1017\/S0033291709990985","volume":"40","author":"F Beacher","year":"2010","unstructured":"Beacher, F. et al. Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study. Psychol. Med. 40, 611\u2013619 (2010).","journal-title":"Psychol. Med."},{"key":"BFnrneurol2013107_CR67","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/01.wnl.0000180958.22678.91","volume":"65","author":"CR Jack Jr","year":"2005","unstructured":"Jack, C. R. Jr et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65, 1227\u20131231 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR68","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","volume":"66","author":"JC Morris","year":"2009","unstructured":"Morris, J. C. et al. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66, 1469\u20131475 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR69","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275\u20131283 (2010).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/tpj.2009.69","volume":"10","author":"AD Roses","year":"2010","unstructured":"Roses, A. D. et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 10, 375\u2013384 (2010).","journal-title":"Pharmacogenomics J."},{"key":"BFnrneurol2013107_CR71","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ng.801","volume":"43","author":"AC Naj","year":"2011","unstructured":"Naj, A. C. et al. Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43, 436\u2013441 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrneurol2013107_CR72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth, P. et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429\u2013435 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrneurol2013107_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117\u2013127 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107\u2013116 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR75","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.neurobiolaging.2006.10.030","volume":"29","author":"T Espeseth","year":"2008","unstructured":"Espeseth, T. et al. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E \u03b54. Neurobiol. Aging 29, 329\u2013340 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR76","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1212\/01.wnl.0000238079.00472.3a","volume":"67","author":"HA Wishart","year":"2006","unstructured":"Wishart, H. A. et al. Regional brain atrophy in cognitively intact adults with a single APOE \u03b54 allele. Neurology 67, 1221\u20131224 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR77","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1176\/ajp.2007.164.6.916","volume":"164","author":"K Chen","year":"2007","unstructured":"Chen, K. et al. Correlations between apolipoprotein E \u03b54 gene dose and whole brain atrophy rates. Am. J. Psychiatry 164, 916\u2013921 (2007).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrneurol2013107_CR78","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJM199603213341202","volume":"334","author":"EM Reiman","year":"1996","unstructured":"Reiman, E. M. et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the \u03b54 allele for apolipoprotein E. N. Engl. J. Med. 334, 752\u2013758 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR79","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1749-6632.1996.tb32600.x","volume":"802","author":"GW Small","year":"1996","unstructured":"Small, G. W. et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann. N. Y. Acad. Sci. 802, 70\u201378 (1996).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrneurol2013107_CR80","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.191044198","volume":"98","author":"MJ de Leon","year":"2001","unstructured":"de Leon, M. J. et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose\/positron-emission tomography (FDG\/PET). Proc. Natl Acad. Sci. USA 98, 10966\u201310971 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR81","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/archneurol.2010.30","volume":"67","author":"JB Langbaum","year":"2010","unstructured":"Langbaum, J. B. et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E \u03b54 allele. Arch. Neurol. 67, 462\u2013468 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR82","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1073\/pnas.090106797","volume":"97","author":"GW Small","year":"2000","unstructured":"Small, G. W. et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 6037\u20136042 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR83","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/archneurol.2011.123","volume":"68","author":"RY Lo","year":"2011","unstructured":"Lo, R. Y. et al. Longitudinal change of biomarkers in cognitive decline. Arch. Neurol. 68, 1257\u20131266 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR84","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1073\/pnas.2635903100","volume":"101","author":"EM Reiman","year":"2004","unstructured":"Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284\u2013289 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR85","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.061509598","volume":"98","author":"EM Reiman","year":"2001","unstructured":"Reiman, E. M. et al. Declining brain activity in cognitively normal apolipoprotein E \u03b54 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 3334\u20133339 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR86","doi-asserted-by":"publisher","first-page":"8299","DOI":"10.1073\/pnas.0500579102","volume":"102","author":"EM Reiman","year":"2005","unstructured":"Reiman, E. M. et al. Correlations between apolipoprotein E \u03b54 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl Acad. Sci. USA 102, 8299\u20138302 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR87","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/2013.jamaneurol.286","volume":"70","author":"HD Protas","year":"2013","unstructured":"Protas, H. D. et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle age persons at three levels of genetic risk for Alzheimer's disease. JAMA Neurol. 70, 320\u2013325 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2013107_CR88","doi-asserted-by":"publisher","first-page":"14770","DOI":"10.1523\/JNEUROSCI.3669-09.2009","volume":"29","author":"AD Cohen","year":"2009","unstructured":"Cohen, A. D. et al. Basal cerebral metabolism may modulate the cognitive effects of A\u03b2 in mild cognitive impairment: an example of brain reserve. J. Neurosci. 29, 14770\u201314778 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR89","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1212\/01.WNL.0000098935.36984.25","volume":"61","author":"RJ Haier","year":"2003","unstructured":"Haier, R. J. et al. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61, 1673\u20131679 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR90","doi-asserted-by":"publisher","unstructured":"Oh, H., Habeck, C., Madison, C. & Jagust, W. Covarying alterations in A\u03b2 deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. http:\/\/dx.doi.org\/10.1002\/hbm.22173 .","DOI":"10.1002\/hbm.22173"},{"key":"BFnrneurol2013107_CR91","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.neuropsychologia.2008.01.026","volume":"46","author":"J Persson","year":"2008","unstructured":"Persson, J. et al. Altered deactivation in individuals with genetic risk for Alzheimer's disease. Neuropsychologia 46, 1679\u20131687 (2008).","journal-title":"Neuropsychologia"},{"key":"BFnrneurol2013107_CR92","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.neuroimage.2009.06.021","volume":"47","author":"AS Fleisher","year":"2009","unstructured":"Fleisher, A. S. et al. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 47, 1678\u20131690 (2009).","journal-title":"Neuroimage"},{"key":"BFnrneurol2013107_CR93","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.1073\/pnas.0811879106","volume":"106","author":"N Filippini","year":"2009","unstructured":"Filippini, N. et al. Distinct patterns of brain activity in young carriers of the APOE-\u03b54 allele. Proc. Natl Acad. Sci. USA 106, 7209\u20137214 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR94","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. et al. Fibrillar amyloid-\u03b2 burden in cognitively normal people at three levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 6820\u20136825 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2013107_CR95","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.neuropsychologia.2011.04.012","volume":"49","author":"KE Pike","year":"2011","unstructured":"Pike, K. E. et al. Cognition and \u03b2-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49, 2384\u20132390 (2011).","journal-title":"Neuropsychologia"},{"key":"BFnrneurol2013107_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne, V. L. et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181\u2013192 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR97","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","volume":"79","author":"MM Mielke","year":"2012","unstructured":"Mielke, M. M. et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 79, 1570\u20131577 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","volume":"34","author":"AS Fleisher","year":"2013","unstructured":"Fleisher, A. S. et al. Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol. Aging 34, 1\u201312 (2013).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR99","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris, J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67, 122\u2013131 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR100","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1212\/WNL.0b013e31824365ab","volume":"78","author":"K Kantarci","year":"2012","unstructured":"Kantarci, K. et al. APOE modifies the association between A\u03b2 load and cognition in cognitively normal older adults. Neurology 78, 232\u2013240 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR101","doi-asserted-by":"publisher","unstructured":"Lim, Y. Y. et al. A\u03b2 amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement. http:\/\/dx.doi.org\/10.1016\/j.jalz.2012.07.004 .","DOI":"10.1016\/j.jalz.2012.07.004"},{"key":"BFnrneurol2013107_CR102","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/archneur.63.7.936","volume":"63","author":"ER Peskind","year":"2006","unstructured":"Peskind, E. R. et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid \u03b2-amyloid 42 in adults with normal cognition. Arch. Neurol. 63, 936\u2013939 (2006).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR103","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-2010-100561","volume":"22","author":"J Popp","year":"2010","unstructured":"Popp, J. et al. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOE \u03b54 genotype. J. Alzheimers Dis. 22, 459\u2013468 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2013107_CR104","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1212\/WNL.0b013e3181bd8271","volume":"73","author":"MI Kester","year":"2009","unstructured":"Kester, M. I. et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353\u20131358 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR105","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X","volume":"48","author":"AM Fagan","year":"2000","unstructured":"Fagan, A. M. et al. Differences in the A\u03b240\/A\u03b242 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 48, 201\u2013210 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR106","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.neurobiolaging.2007.08.019","volume":"30","author":"L Glodzik-Sobanska","year":"2009","unstructured":"Glodzik-Sobanska, L. et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol. Aging 30, 672\u2013681 (2009).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR107","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.biopsych.2007.05.030","volume":"63","author":"L Mosconi","year":"2008","unstructured":"Mosconi, L. et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol. Psychiatry 63, 609\u2013618 (2008).","journal-title":"Biol. Psychiatry"},{"key":"BFnrneurol2013107_CR108","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1037\/a0026769","volume":"26","author":"A Ihle","year":"2012","unstructured":"Ihle, A., Bunce, D. & Kliegel, M. APOE \u03b54 and cognitive function in early life: a meta-analysis. Neuropsychology 26, 267\u2013277 (2012).","journal-title":"Neuropsychology"},{"key":"BFnrneurol2013107_CR109","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0197-4580(03)00006-X","volume":"24","author":"LC Baxter","year":"2003","unstructured":"Baxter, L. C., Caselli, R. J., Johnson, S. C., Reiman, E. & Osborne, D. Apolipoprotein E \u03b54 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol. Aging 24, 947\u2013952 (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR110","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1212\/01.WNL.0000129533.26544.BF","volume":"62","author":"RJ Caselli","year":"2004","unstructured":"Caselli, R. J. et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE \u03b54 allele. Neurology 62, 1990\u20131995 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neulet.2005.11.070","volume":"396","author":"J Lind","year":"2006","unstructured":"Lind, J. et al. Reduced hippocampal volume in non-demented carriers of the apolipoprotein E \u03b54: relation to chronological age and recognition memory. Neurosci. Lett. 396, 23\u201327 (2006).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol2013107_CR112","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/archneur.64.9.1306","volume":"64","author":"RJ Caselli","year":"2007","unstructured":"Caselli, R. J. et al. Cognitive domain decline in healthy apolipoprotein E \u03b54 homozygotes before the diagnosis of mild cognitive impairment. Arch. Neurol. 64, 1306\u20131311 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR113","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMoa0809437","volume":"361","author":"RJ Caselli","year":"2009","unstructured":"Caselli, R. J. et al. Longitudinal modeling of age-related memory decline and the APOE \u03b54 effect. N. Engl. J. Med. 361, 255\u2013263 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2013107_CR114","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1212\/WNL.0b013e3182167147","volume":"76","author":"RJ Caselli","year":"2011","unstructured":"Caselli, R. J. et al. Longitudinal modeling of frontal cognition in APOE \u03b54 homozygotes, heterozygotes, and noncarriers. Neurology 76, 1383\u20131388 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR115","unstructured":"Human Genome Variation Society. Alzheimer's Disease and Frontotemporal Dementia Mutation Database [online] , (2013)."},{"key":"BFnrneurol2013107_CR116","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1086\/302553","volume":"65","author":"D Campion","year":"1999","unstructured":"Campion, D. et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664\u2013670 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol2013107_CR117","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI25247","volume":"115","author":"JR Cirrito","year":"2005","unstructured":"Cirrito, J. R. et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-\u03b2 deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115, 3285\u20133290 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2013107_CR118","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneurol2013107_CR119","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/archneur.59.9.1381","volume":"59","author":"H Fukumoto","year":"2002","unstructured":"Fukumoto, H., Cheung, B. S., Hyman, B. T. & Irizarry, M. C. \u03b2-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381\u20131389 (2002).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR120","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archneur.62.7.1097","volume":"62","author":"AK Godbolt","year":"2005","unstructured":"Godbolt, A. K. et al. Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. Arch. Neurol. 62, 1097\u20131101 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR121","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ajgp.12.2.146","volume":"12","author":"A Lleo","year":"2004","unstructured":"Lleo, A., Berezovska, O., Growdon, J. H. & Hyman, B. T. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. J. Geriatr. Psychiatry 12, 146\u2013156 (2004).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2013107_CR122","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1016\/j.jalz.2011.05.618","volume":"7","author":"Y Quiroz","year":"2011","unstructured":"Quiroz, Y. et al. Cortical signature of Alzheimer's disease-related thinning in presymptomatic presenilin-1 mutation carriers. Alzheimers Dement. 7, S220 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR123","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11, 1048\u20131056 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR124","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1749-6632.1996.tb34423.x","volume":"777","author":"NC Fox","year":"1996","unstructured":"Fox, N. C., Warrington, E. K., Stevens, J. M. & Rossor, M. N. Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann. N. Y. Acad. Sci. 777, 226\u2013232 (1996).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrneurol2013107_CR125","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/brain\/119.6.2001","volume":"119","author":"NC Fox","year":"1996","unstructured":"Fox, N. C. et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119, 2001\u20132007 (1996).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR126","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0304-3940(95)11270-7","volume":"186","author":"AM Kennedy","year":"1995","unstructured":"Kennedy, A. M. et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186, 17\u201320 (1995).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol2013107_CR127","first-page":"1778","volume":"47","author":"L Mosconi","year":"2006","unstructured":"Mosconi, L. et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 47, 1778\u20131786 (2006).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2013107_CR128","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.neurobiolaging.2009.08.016","volume":"32","author":"M Sch\u00f6ll","year":"2011","unstructured":"Sch\u00f6ll, M. et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging 32, 1388\u20131399 (2011).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR129","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk, W. E. et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27, 6174\u20136184 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR130","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archneurol.2009.285","volume":"66","author":"VL Villemagne","year":"2009","unstructured":"Villemagne, V. L. et al. High striatal amyloid \u03b2-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 66, 1537\u20131544 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000335729","volume":"33","author":"JM Ringman","year":"2012","unstructured":"Ringman, J. M. et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 1\u20135 (2012).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrneurol2013107_CR132","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1093\/brain\/awq148","volume":"133","author":"MA Parra","year":"2010","unstructured":"Parra, M. A. et al. Visual short-term memory binding deficits in familial Alzheimer's disease. Brain 133, 2702\u20132713 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR133","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/13803390601174151","volume":"29","author":"JC Arango-Lasprilla","year":"2007","unstructured":"Arango-Lasprilla, J. C., Cuetos, F., Valencia, C., Uribe, C. & Lopera, F. Cognitive changes in the preclinical phase of familial Alzheimer's disease. J. Clin. Exp. Neuropsychol. 29, 892\u2013900 (2007).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"BFnrneurol2013107_CR134","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.57.8.967","volume":"57","author":"SK Newman","year":"1994","unstructured":"Newman, S. K., Warrington, E. K., Kennedy, A. M. & Rossor, M. N. The earliest cognitive change in a person with familial Alzheimer's disease: presymptomatic neuropsychological features in a pedigree with familial Alzheimer's disease confirmed at necropsy. J. Neurol. Neurosurg. Psychiatry 57, 967\u2013972 (1994).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2013107_CR135","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/01.wnl.0000172919.50001.d6","volume":"65","author":"JM Ringman","year":"2005","unstructured":"Ringman, J. M. et al. Neuropsychological function in nondemented carriers of presenilin-1 mutations. Neurology 65, 552\u2013558 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR136","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(10)70323-9","volume":"10","author":"N Acosta-Baena","year":"2011","unstructured":"Acosta-Baena, N. et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 10, 213\u2013220 (2011).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR137","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike, K. E. et al. \u03b2-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837\u20132844 (2007).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR138","doi-asserted-by":"publisher","unstructured":"Johnson, K. A. et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. http:\/\/dx.doi.org\/10.1016\/j.jalz.2012.10.007 .","DOI":"10.1016\/j.jalz.2012.10.007"},{"key":"BFnrneurol2013107_CR139","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446\u2013452 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR140","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.22608","volume":"70","author":"AG Vlassenko","year":"2011","unstructured":"Vlassenko, A. G. et al. Amyloid-\u03b2 plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann. Neurol. 70, 857\u2013861 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR141","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neurobiolaging.2012.06.014","volume":"34","author":"RA Sperling","year":"2013","unstructured":"Sperling, R. A. et al. Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol. Aging 34, 822\u2013831 (2013).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR142","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509\u20131517 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR143","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.21904","volume":"67","author":"DM Rentz","year":"2010","unstructured":"Rentz, D. M. et al. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 67, 353\u2013364 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR144","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","volume":"74","author":"SM Resnick","year":"2010","unstructured":"Resnick, S. M. et al. Longitudinal cognitive decline is associated with fibrillar amyloid- \u03b2 measured by [11C]PiB. Neurology 74, 807\u2013815 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR145","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/archneurol.2009.272","volume":"66","author":"M Storandt","year":"2009","unstructured":"Storandt, M., Mintun, M. A., Head, D. & Morris, J. C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-\u03b2 peptide deposition identified with Pittsburgh compound B: cognitive decline associated with A\u03b2 deposition. Arch. Neurol. 66, 1476\u20131481 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR146","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3233\/JAD-122170","volume":"34","author":"KA Ellis","year":"2013","unstructured":"Ellis, K. A. et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-\u03b2. J. Alzheimers Dis. 34, 861\u2013871 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2013107_CR147","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3233\/JAD-2012-121516","volume":"33","author":"YY Lim","year":"2013","unstructured":"Lim, Y. Y. et al. Rapid decline in episodic memory in healthy older adults with high amyloid-\u03b2. J. Alzheimers Dis. 33, 675\u2013679 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2013107_CR148","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archneur.57.6.808","volume":"57","author":"MF Elias","year":"2000","unstructured":"Elias, M. F. et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch. Neurol. 57, 808\u2013813 (2000).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR149","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1212\/01.WNL.0000147470.58328.50","volume":"63","author":"J Saxton","year":"2004","unstructured":"Saxton, J. et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63, 2341\u20132347 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR150","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/archneurol.2011.31","volume":"68","author":"RS Wilson","year":"2011","unstructured":"Wilson, R. S., Leurgans, S. E., Boyle, P. A. & Bennett, D. A. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch. Neurol. 68, 351\u2013356 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR151","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jalz.2012.05.1134","volume":"8","author":"R Sperling","year":"2012","unstructured":"Sperling, R., Donohue, M. & Aisen, P. The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer's disease. Alzheimers Dement. 8, 425\u2013426 (2012).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR152","doi-asserted-by":"publisher","first-page":"S502","DOI":"10.1016\/j.jalz.2011.05.2401","volume":"7","author":"JB Langbaum","year":"2011","unstructured":"Langbaum, J. B. et al. Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects in APOE4 carriers: findings from the Alzheimer's prevention initiative. Alzheimers Dement. 7, S502 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR153","doi-asserted-by":"publisher","first-page":"S608","DOI":"10.1016\/j.jalz.2011.05.1729","volume":"7","author":"N Ayutyanont","year":"2011","unstructured":"Ayutyanont, N. et al. Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects: findings in the Colombian kindred with the E280A Presenilin 1 mutation and the Alzheimer's Prevention Initiative. Alzheimers Dement. 7, S608 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2013107_CR154","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1212\/01.WNL.0000147469.18313.3B","volume":"63","author":"L Mosconi","year":"2004","unstructured":"Mosconi, L. et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63, 2332\u20132340 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR155","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00259-003-1194-1","volume":"30","author":"A Drzezga","year":"2003","unstructured":"Drzezga, A. et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30, 1104\u20131113 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2013107_CR156","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.neurobiolaging.2005.07.003","volume":"27","author":"MJ de Leon","year":"2006","unstructured":"de Leon, M. J. et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394\u2013401 (2006).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR157","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr","year":"2009","unstructured":"Jack, C. R. Jr et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355\u20131365 (2009).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR158","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ana.20163","volume":"56","author":"BC Dickerson","year":"2004","unstructured":"Dickerson, B. C. et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 56, 27\u201335 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR159","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.1523\/JNEUROSCI.2250-06.2006","volume":"26","author":"KA Celone","year":"2006","unstructured":"Celone, K. A. et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J. Neurosci. 26, 10222\u201310231 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2013107_CR160","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"JJ Palop","year":"2007","unstructured":"Palop, J. J. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697\u2013711 (2007).","journal-title":"Neuron"},{"key":"BFnrneurol2013107_CR161","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tics.2011.09.004","volume":"15","author":"WJ Jagust","year":"2011","unstructured":"Jagust, W. J. & Mormino, E. C. Lifespan brain activity, \u03b2-amyloid, and Alzheimer's disease. Trends Cogn. Sci. 15, 520\u2013526 (2011).","journal-title":"Trends Cogn. Sci."},{"key":"BFnrneurol2013107_CR162","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1093\/brain\/awl281","volume":"129","author":"WE Klunk","year":"2006","unstructured":"Klunk, W. E., Mathis, C. A., Price, J. C., Lopresti, B. J. & DeKosky, S. T. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2805\u20132807 (2006).","journal-title":"Brain"},{"key":"BFnrneurol2013107_CR163","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","volume":"69","author":"G Li","year":"2007","unstructured":"Li, G. et al. CSF tau\/A\u03b242 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69, 631\u2013639 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR164","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg, A. et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456\u20131465 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2013107_CR165","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393 (2009).","journal-title":"JAMA"},{"key":"BFnrneurol2013107_CR166","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser, P. J. et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8, 619\u2013627 (2009).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2013107_CR167","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ana.21598","volume":"65","author":"DA Wolk","year":"2009","unstructured":"Wolk, D. A. et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65, 557\u2013568 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2013107_CR168","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","volume":"73","author":"P Vemuri","year":"2009","unstructured":"Vemuri, P. et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287\u2013293 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR169","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","volume":"73","author":"P Vemuri","year":"2009","unstructured":"Vemuri, P. et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73, 294\u2013301 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR170","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","volume":"79","author":"IA van Rossum","year":"2012","unstructured":"van Rossum, I. A. et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79, 1809\u20131816 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR171","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","volume":"80","author":"A Prestia","year":"2013","unstructured":"Prestia, A. et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80, 1048\u20131056 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR172","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","volume":"80","author":"CM Roe","year":"2013","unstructured":"Roe, C. M. et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784\u20131791 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR173","doi-asserted-by":"publisher","first-page":"e58816","DOI":"10.1371\/journal.pone.0058816","volume":"8","author":"KA Andrews","year":"2013","unstructured":"Andrews, K. A. et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS ONE 8, e58816 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2013107_CR174","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher, A. S. et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 68, 1404\u20131411 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2013107_CR175","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","volume":"64","author":"NC Fox","year":"2005","unstructured":"Fox, N. C. et al. Effects of A\u03b2 immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563\u20131572 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2013107_CR176","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921\u2013923 (1993).","journal-title":"Science"},{"key":"BFnrneurol2013107_CR177","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders, A. M. et al. Association of apolipoprotein E allele \u03b54 with late\u2010onset familial and sporadic Alzheimer's disease. Neurology 43, 1467\u20131472 (1993).","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1038\/nrneurol.2013.145","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000}}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2013.107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2013.107","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2013.107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T05:53:29Z","timestamp":1715493209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2013.107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":177,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnrneurol2013107"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2013.107","relation":{"correction":[{"id-type":"doi","id":"10.1038\/nrneurol.2013.145","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]},"assertion":[{"value":"11 June 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2013","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, the appropriate references to support the following sentence were omitted, and incorrect references were cited:\"By contrast, possession of one copy of the \u03b54 allele, which is found in about 25% of the population and about 60% of patients with AD dementia, is associated with higher risk of late-onset AD and younger age at dementia onset, and individuals with two copies of this allele have an especially high risk of AD.\"The references that should have been cited are:Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science261, 921-923 (1993).Saunders, A. M. et al. Association of apolipoprotein E allele \u03b54 with late-onset familial and sporadic Alzheimer's disease. Neurology43, 1467-1472 (1993).The error has been corrected for the HTML and PDF versions of the article.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J. B. Langbaum has received consulting fees from Janssen Alzheimer Immunotherapy. A. S. Fleisher has received consulting fees from Eli Lilly, Avid, Merck, Grifols, Quintiles; has been an invited speaker for Siemens, Quintiles, Avid; has Data and Safety Monitoring Board membership with Merck, Pfizer; has received grant funding from Lilly; has been involved in studies sponsored by Merck, Roche, Genentech, Pfizer, Avanir, Takeda, Lilly, BMS, Baxter, Neuroptix, Wyeth. Y. T. Quiroz serves as a consultant to Medavante. P. N. Tariot has received consulting fees from Abbott Laboratories, AC Immune, Adamas, Boehringer-Ingelheim, California Pacific Medical Center, Chase Pharmaceuticals, Chiesi, CME, Eisai, Elan, Medavante, Merz, Otsuka, Sanofi-Aventis; has received consulting fees and research support from AstraZeneca, Avanir, Avid, Bristol Myers Squibb, Cognoptix, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Medivation, Merck and Company, Pfizer, Roche; has received research support only from Baxter Healthcare Corp., Functional Neuromodulation, GE Healthcare, Medavante, Targacept, Toyama; has stock options in Adamas; and is listed as a contributor to a patent owned by the University of Rochester, 'Biomarkers of Alzheimer's Disease.' E. M. Reiman has been a Scientific Advisor for AstraZeneca, Baxter, Bayer, Eisai, Elan, Eli Lilly, GlaxoSmithKline, Intellect, Novartis, Siemens, Takeda; has research contracts with Avid\/Eli Lilly and Genentech Research Grants; and has a patent pending for a biomarker strategy for the evaluation of presymptomatic AD treatments (through Banner Health). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}